Here are 1-3 brief analogies to describe Phreesia (PHR):

• It's like Square for healthcare practices, providing digital tools for patient check-in, forms, and payment processing.

• Think of it as TurboTax for patient intake, simplifying all the forms and administrative tasks for doctor visits.

• It's the Shopify for healthcare's patient management, offering an all-in-one digital platform for patient engagement and payments.

• Phreesia Platform: An integrated SaaS-based software and payment platform designed to manage the patient intake process and process patient payments for the healthcare industry.
• Registration Solution: Automates patient self-registration, streamlining the initial patient encounter.
• Revenue Cycle Solution: Optimizes financial operations through insurance verification, point-of-sale payments applications, and cost estimation tools.
• Access Solutions: Enhances patient access to care with appointment scheduling, reminders, and referral tracking functionalities.
• Life Sciences Solution: Delivers targeted and clinically relevant marketing content from pharmaceutical, medical device, and biotechnology companies to patients.
• Clinical Support Solution: Collects clinical intake and patient-reported outcome data across specialties and facilitates patient communication.
• COVID-19 Support Modules: Provides tools for managing COVID-19 vaccine delivery, screening, contactless check-in, and telehealth intake.

Phreesia (PHR) sells its integrated SaaS-based software and payment platform primarily to other companies within the healthcare and life sciences industries. The provided background information does not list the specific names of individual customer companies.

Its major customer categories include:

• Healthcare Service Providers: This category encompasses single-specialty practices, multi-specialty groups, and health systems that utilize Phreesia's platform to manage patient intake and other administrative processes.
• Life Sciences Companies: This category includes pharmaceutical, medical device, and biotechnology companies that leverage Phreesia's platform for solutions such as delivering targeted marketing content to patients.

Major Suppliers:

• Amazon Web Services (parent company: Amazon.com, Inc., AMZN)

Chaim Indig, Chief Executive Officer and Board Member

Chaim Indig co-founded Phreesia in 2005 and has served as its Chief Executive Officer and a member of its Board since. He has dedicated his career to improving healthcare for patients, providers, and staff. Under his leadership, Phreesia has grown its national presence, formed strategic partnerships with major healthcare companies, and received recognition for its role in enhancing care efficiency and patient-centeredness. He also led Phreesia through its initial public offering in 2019. Prior to co-founding Phreesia, Indig spearheaded the introduction of the analytics software company, Spotfire, Inc., into the pharmaceutical marketing space.

Balaji Gandhi, Chief Financial Officer

Balaji Gandhi has been the Chief Financial Officer of Phreesia since March 24, 2023, and brings over 25 years of executive experience to oversee the company's financial operations, including budgeting, forecasting, reporting, analysis, internal controls, and investor relations. Before joining Phreesia, he spent nearly a decade in leadership roles at companies such as Madaket Health, Press Ganey, and Fresenius Medical Care, focusing on finance, corporate development, strategy, and investor relations. He also served as an investment research analyst in the healthcare services market for more than ten years at firms including Deutsche Bank, GE Capital, and Oppenheimer & Co., Inc. His prior roles at Phreesia included leading Investor Relations, and he was also CFO at Madaket Inc.

Evan Roberts, President, Provider Solutions

Evan Roberts co-founded Phreesia in 2005 and has since led the company's efforts to deliver the highest value to its clients. He oversees Phreesia's ongoing operations and procedures. Before co-founding Phreesia, Roberts was a senior sales engineer at Spotfire, where he was instrumental in penetrating new markets and generating significant revenue.

Jack Callahan, Chief Technology Officer

Jack Callahan joined Phreesia in 2010. As Chief Technology Officer, he is responsible for Phreesia's core and integration platforms, overseeing the company's Patient Intake, Data Center Operations, Site Reliability Engineering, and Analytics teams. Previously, Callahan worked as a developer and architect at Spotfire, where he was part of the professional services team, assisting clients across various industries with data gathering and analysis.

David Linetsky, Senior Vice President, Network Solutions

David Linetsky is responsible for fostering Phreesia's partnerships with life sciences companies, advocacy groups, government agencies, and other organizations to support the development of valuable healthcare products that engage patients. He has been with Phreesia for over a decade, holding key leadership positions including Vice President of Analytics and Insights, and Vice President of Finance. Prior to his tenure at Phreesia, Linetsky worked in academia as a researcher and instructor in the fields of biotechnology, mathematics, and philosophy. He has served as SVP since March 2019, following earlier roles in analytics and finance since 2008, and worked as an intern/consultant from 2005–2008, becoming an executive officer in July 2019.

A clear emerging threat to Phreesia comes from the ongoing trend of dominant Electronic Health Record (EHR) vendors significantly expanding and improving their native capabilities in patient intake, payment processing, appointment scheduling, and patient communication. As healthcare providers seek to consolidate vendors and streamline workflows within their existing, indispensable EHR systems, enhanced functionality from these major EHR players (such as Epic, Cerner, Athenahealth, etc.) could directly compete with and potentially reduce the need for a separate, specialized platform like Phreesia.

Phreesia, Inc. (PHR) operates within several significant addressable markets primarily within the United States, including patient intake software, patient engagement solutions, healthcare digital payments, and healthcare provider financing.

• The **U.S. patient intake software market** was valued at approximately USD 1.71 billion in 2024 and is projected to grow to about USD 5.66 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 14.2% from 2025 to 2033.
• The **U.S. patient engagement solutions market**, which encompasses many of Phreesia's offerings, was estimated at USD 7.40 billion in 2025 and is anticipated to reach approximately USD 25.21 billion by 2034, with a CAGR of 14.68% from 2025 to 2034. Other estimates place the U.S. patient engagement solutions market at USD 7.59 billion in 2024, growing to USD 22.41 billion by 2030 at a CAGR of 19.77% from 2025 to 2030.
• For **healthcare digital payments**, the U.S. market size was approximately USD 3.98 billion in 2024 and is projected to reach around USD 26.83 billion by 2034, with a CAGR of 21.02% from 2025 to 2034. Globally, this market was valued at USD 14.21 billion in 2024 and is expected to grow to USD 94.15 billion by 2034, with North America holding the largest market share (40%) in 2024.
• Phreesia has also identified a "multibillion dollar" opportunity in **healthcare provider (HCP) digital marketing** within its emerging products.
• Following its acquisition of AccessOne, Phreesia has expanded into the **provider financing market**, which addresses a large segment of U.S. healthcare, connected to an estimated USD 74 billion in out-of-pocket patient spend by 2032.

Phreesia (PHR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Growth in Healthcare Services Clients (AHSCs): Phreesia consistently emphasizes the expansion of its client base as a primary growth driver. The company expects to increase its average number of healthcare services clients (AHSCs) to approximately 4,515 for fiscal year 2026 and projects mid-single-digit growth in AHSCs for fiscal year 2027. This indicates a continued focus on acquiring new healthcare provider clients.
2. Increased Revenue per Client: A significant driver of revenue growth is the deepening of relationships with existing clients and the monetization of their services. Phreesia aims to increase the revenue generated from each average healthcare services client (AHSC) by cross-selling new applications and expanding its footprint within current client organizations. Total revenue per AHSC increased by 6% year-over-year in Q3 Fiscal Year 2026, and the company anticipates low-double-digit percentage growth in total revenue per AHSC for fiscal year 2027.
3. Expansion of Network Solutions: Phreesia's Network Solutions segment is a key area for future growth, with its revenue growth often outpacing that of healthcare services clients. These solutions involve fees for targeted digital marketing delivered to patients through the Phreesia platform. Network solutions are projected to be the fastest-growing segment in fiscal year 2027.
4. Growth in Payment Processing and Strategic Acquisitions: The expansion of Phreesia's integrated payments solution, driven by increased patient payment volumes, is a vital revenue stream. The acquisition of AccessOne in November 2025 is a notable strategic move, expanding Phreesia's payment solutions to include patient access and provider financing. This acquisition is expected to contribute approximately $7.5 million to fiscal year 2026 revenue and 6.5% of projected revenue for fiscal year 2027, enhancing payment capabilities and supporting margin expansion.
5. New Product and Service Innovation: Phreesia continuously invests in developing and launching new products and services to enhance its platform and deepen client relationships. Examples include solutions aimed at improving medication adherence and new post-script engagement products, which are expected to generate additional revenue. This ongoing innovation helps Phreesia address evolving healthcare industry needs and expand its offerings.

Share Repurchases

• Phreesia's Board of Directors authorized a stock repurchase program on March 12, 2025, allowing for the repurchase of up to 2.5 million shares of common stock.
• This repurchase program does not obligate the company to acquire a specific number or dollar value of shares and may be altered or discontinued at any time.

Share Issuance

• The number of outstanding common shares increased from 56,387,472 as of March 6, 2024, to 58,772,448 as of March 7, 2025.
• Outstanding common shares further increased to 59,914,473 as of August 29, 2025.

Outbound Investments

• Phreesia completed the acquisition of AccessOne in September 2025 for approximately $160 million in cash.
• The AccessOne acquisition was funded by $50 million from Phreesia's existing cash balance, approximately $107 million from a new bridge loan, and $6 million in cash acquired from AccessOne.
• Phreesia has made a total of 4 acquisitions, with peak activity in 2023 (2 acquisitions), followed by 2025 (1 acquisition) and 2021 (1 acquisition).

Capital Expenditures

• Phreesia's capital expenditures averaged $9.782 million annually for the fiscal years ending January 2021 to 2025.
• Capital expenditures reached a high of $18.42 million in January 2022 and a low of $4.732 million in January 2023.
• The company's latest twelve months capital expenditures stand at $11.332 million.